Indian Journal of Clinical Biochemistry

, Volume 24, Issue 1, pp 98–101

Oxidative stress in Parkinson’s disease

  • Shashikant Nikam
  • Padmaja Nikam
  • S. K. Ahaley
  • Ajit V. Sontakke
Article

Abstract

Oxidative stress contributes to the cascade, leading to dopamine cell degeneration in Parkinson’s disease. However, oxidative stress is intimately linked to other components of the degenerative process, such as mitochondrial dysfunction, excitotoxicity, nitric oxide toxicity and inflammation. It is therefore difficult to determine whether oxidative stress leads to or is a consequence of, these events. Oxidative stress was assessed by estimating lipid peroxidation product in the form of thiobarbituric acid reactive substances, nitric oxide in the form of nitrite & nitrate. Enzymatic antioxidants in the form of superoxide dismutase, glutathione peroxidase, catalase, ceruloplasmin and non enzymatic antioxidant vitamins e.g. vitamin E and C in either serum or plasma or erythrocyte in 40 patients of Parkinson’s disease in the age group 40–80 years. Trace elements e.g. copper, zinc and selenium were also estimated. Plasma thiobarbituric acid reactive substances and nitric oxide levels were Significantly high but superoxide dismutase, glutathione peroxidase, catalase, ceruloplasmin, vitamin-E, vitamin-C, copper, zinc and selenium levels were significantly low in Parkinson’s disease when compared with control subjects. Present study showed that elevated oxidative stress may be playing a role in dopaminergic neuronal loss in substentia nigra pars compacta and involved in pathogenesis of the Parkinson’s disease.

Key Words

Oxidative stress Antioxidants Pathogenesis Parkinson’s disease 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Martin JB. Moleculor basis of the neurodegenerative disorder. New Eng J Med 1999; 340(25):1970–1980.PubMedCrossRefGoogle Scholar
  2. 2.
    Pioro EP. Antioxidant therapy in ALS. Amyotrophic Lateral Scleorsis 2000; 1 (Supl): 5–15.CrossRefGoogle Scholar
  3. 3.
    Kowall W, Ferante RJ, Martin JB. Patterns of cells in Huntington’s disease. Trends Neurosci 1987;10: 42–49.CrossRefGoogle Scholar
  4. 4.
    Mmosley RL, Benner EJ, Irena. Neuroinflammation, oxidative stress and the pathogenesis of Parkinson’s disease. Clin Neurochem Res 2006; 6(5):261–281.Google Scholar
  5. 5.
    Jellinger K. Pathology of Parkinson’s disease, changes other than the nigrostritalpathway. Ann Neural 1992; 14: 153–97.Google Scholar
  6. 6.
    Forne LS. Pathology of Parkinson’s disease and importance of substentia nigra and Lewy bodies. Aetiology of Parkinson’s disease. Ed. Sterm. G. Baltimore Johns Hopkins Press: 1990; p 185–238.Google Scholar
  7. 7.
    Kurtz JF. An overview of epidemiology of Parkinsonism. Progress inParkinson’s disease research. Eds. Hefti F. Weiner W.J. Mount Kisw Futura Publishing Company. 1992; p-119–p-169.Google Scholar
  8. 8.
    Munch G. Oxidative stress and advanced glycation end products. Alzheimer’s Disease Review 1996;1:71–74.Google Scholar
  9. 9.
    Benecke R, Strumper P, Weiss H. Electron transport complex CI & IV of platelets are abnormal in Parkinson’s disease. Brain 1993;116;1451–1463.PubMedCrossRefGoogle Scholar
  10. 10.
    Buege JA, Aust AD. Microsomal lipid peroxidation.In methods Enzymeol Estbrook RW, Pullman ME. New York: Acad Press 1987;302–310Google Scholar
  11. 11.
    Cortas, Walkid. Determination of nitrate in serum and urine by kinetic cadmium reduction method. Clin Chem 1990;38(8pt.1); 1440–1443.Google Scholar
  12. 12.
    Randox Ltd. Determination of superoxide dismutase & Glutathione peroxide. Tech Bull on free radical 1994; 12–14.Google Scholar
  13. 13.
    Aebi H. Catalase. In methods, in enzymatic analysis (ed) Bergmeryer HU. Vol. 3. Acadamic press New York 1983; 276–286.Google Scholar
  14. 14.
    Karl H, Smith BSW, Wright H. Colorimetric method for serum Ceruloplasmin. Clin Chem 1974; 50: 359–366.CrossRefGoogle Scholar
  15. 15.
    Baker Frank. Vitamin E. In clinical vitaminology methods & interpretation, Interscience publishers, New York 1968; 169–176.Google Scholar
  16. 16.
    Natelson S. Ascorbic acid. In techniques of clinical chemistry, 3rd Edition, Charles C Thomas, Illinios USA 1971;162–165.Google Scholar
  17. 17.
    Fahn S. Parkinson’s disease and other basal ganglion disorders. IN: Disease of nervous system. Clin Neurol. Eds.: Asbury AK et. al. W.B. Saunders company. 1992; 1144–1158.Google Scholar
  18. 18.
    Ratan RR, Baraban JM. Apoptotic death in an invitro model of neuronal oxidative stress. Clin Ext Pharmacol Physical 1995; 309–310.Google Scholar
  19. 19.
    Mecocci. The oxidative damage mitochondrial DNA shows age dependent increase in human brain. Ann Neural 1993:34; 159–163.CrossRefGoogle Scholar
  20. 20.
    Floryed RA Antioxidants, oxidative stress and degenerative neurological disorders. Proc Soc Exper Biol Med 1999; 222(3): 236–245CrossRefGoogle Scholar
  21. 21.
    Behl C, Davis J, Cole GM. Vitamin E protects nerves cells from amyloid beta protein toxicity. Biochem Biophy Res Commun 1992; 186: 944–950.CrossRefGoogle Scholar
  22. 22.
    Brown R. ALS and the inherited motor neurons disease. Mol Neurol. New York Scientific Americam 1998; 223:38.Google Scholar
  23. 23.
    Burke RE. Apoptosis in degenerative disease of the basal ganglia. Neurosciertist 1998; 4:301–311.Google Scholar
  24. 24.
    Bhumik D, Medin J, Colmenms G. Mutational analysis of active site residue of human adenosine deaminase. J Biol Chem 1993; 8268: 5461–5470.Google Scholar

Copyright information

© Association of Clinical Biochemists of India 2009

Authors and Affiliations

  • Shashikant Nikam
    • 1
    • 3
  • Padmaja Nikam
    • 1
  • S. K. Ahaley
    • 1
  • Ajit V. Sontakke
    • 2
  1. 1.Department of BiochemistryGovernment Medical CollegeMirajIndia
  2. 2.KIMSKaradIndia
  3. 3.Department of BiochemistryBelgaum Institute of Medical SciencesBelgaumIndia

Personalised recommendations